Abstract
Three different classes of aryl hydroxamic acid scaffolds have been explored and provided potent inhibitors of MMP-1, -2, -9, -13 and TACE. Structure-based design has allowed the evolution of these inhibitors from broad spectrum inhibitors into compounds that are more selective for MMPs relevant to particular disease states. Aryl hydroxamates selective for MMP-9, MMP-13 and TACE have been disclosed that may aid in the study of the physiological role of these enzymes. Furthermore, the different selectivity profiles offered by these MMP / TACE inhibitors may allow the determination of which metalloprotease, or group of metalloproteases, must be inhibited for the safe, long-term treatment of osteoarthritis, rheumatoid arthritis and cancer. Some of these compounds have demonstrated useful biological activity in efficacy models relevant to osteoarthritis and rheumatoid arthritis and are therefore potential clinical candidates.
Keywords: aryl hydroxamic acids, aryl hydroxamates, mmp inhibitor, tace inhibitor, anthranilic acid
Current Topics in Medicinal Chemistry
Title: The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE
Volume: 4 Issue: 12
Author(s): Jeremy I. Levin
Affiliation:
Keywords: aryl hydroxamic acids, aryl hydroxamates, mmp inhibitor, tace inhibitor, anthranilic acid
Abstract: Three different classes of aryl hydroxamic acid scaffolds have been explored and provided potent inhibitors of MMP-1, -2, -9, -13 and TACE. Structure-based design has allowed the evolution of these inhibitors from broad spectrum inhibitors into compounds that are more selective for MMPs relevant to particular disease states. Aryl hydroxamates selective for MMP-9, MMP-13 and TACE have been disclosed that may aid in the study of the physiological role of these enzymes. Furthermore, the different selectivity profiles offered by these MMP / TACE inhibitors may allow the determination of which metalloprotease, or group of metalloproteases, must be inhibited for the safe, long-term treatment of osteoarthritis, rheumatoid arthritis and cancer. Some of these compounds have demonstrated useful biological activity in efficacy models relevant to osteoarthritis and rheumatoid arthritis and are therefore potential clinical candidates.
Export Options
About this article
Cite this article as:
Levin I. Jeremy, The Design and Synthesis of Aryl Hydroxamic Acid Inhibitors of MMPs and TACE, Current Topics in Medicinal Chemistry 2004; 4 (12) . https://dx.doi.org/10.2174/1568026043387935
DOI https://dx.doi.org/10.2174/1568026043387935 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Application of 3D Biomimetic Models in Drug Delivery and Regenerative Medicine
Current Pharmaceutical Design Defining Novel Targets for Intervention in Rheumatoid Arthritis: An Overview
Current Rheumatology Reviews Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods
Cardiovascular & Hematological Agents in Medicinal Chemistry Is There a Genetic Susceptibility to Bronchopulmonary Dysplasia?
Current Respiratory Medicine Reviews Purification and Characterizaion of Buffalo Brain Cystatin
Protein & Peptide Letters Formulation and Assessment of In Vivo Anti-Inflammatory Potential of Omega-3-Fatty Acid Loaded Self Emulsifying Nanoemulsion
Current Nanomedicine Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Microneedle-Based Drug Delivery Systems for Transdermal Route
Current Drug Targets Toll Like Receptor - Potential Drug Targets in Infectious Disease
Infectious Disorders - Drug Targets Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Recent advances in the management of autoimmune myocarditis: insights from animal studies.
Current Pharmaceutical Design Luteolin, a Flavonoid with Potential for Cancer Prevention and Therapy
Current Cancer Drug Targets Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Lifestyle Choices and Endothelial Function: Risk and Relevance
Current Vascular Pharmacology Natural Compounds A Weapon to Ameliorate Breast Cancer Cells: A Review
Anti-Cancer Agents in Medicinal Chemistry Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Reflections on MicroRNAs in Chronic Pulmonary Disease: Looking into the miR-ror and Crystal Ball
Inflammation & Allergy - Drug Targets (Discontinued) Formulating SLN and NLC as Innovative Drug Delivery Systems for Non-Invasive Routes of Drug Administration
Current Medicinal Chemistry Current and Future Pharmaceutical Therapy for Rheumatoid Arthritis
Current Pharmaceutical Design 3,4-Dihydropyrimidin-2(1H)-one C5 Amides as Inhibitors of T NFα Production: Synthesis, Biological Evaluation and Molecular Modeling
Letters in Drug Design & Discovery